arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Ocugen, Inc.

OCGN
$1.27 ▲ +0.02 (+2.00%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
50 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
86
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Ocugen, Inc. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $416.0M
Dividend Yield
Revenue Growth 3.5%
Op. Margin
ROIC -47.0%
FCF / Share $-0.07
Trailing P/E
Price / Book 74.0x
FCF Yield
Debt / Equity 4.17
info Valuation on last close. End-of-day price, Aug 7, 2026.

50-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.53M
↑ +3.5%
Net Income Profit after all expenses
$-19.18M
↓ -24.9%
FCF / Share Free cash flow per share
$-0.07
↓ -32.2%
Long-Term Debt Long-term obligations
$24.19M
↓ -12.2%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Financial Health
100
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 50 quarters